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Prediction modelsThe debate as to the true risk of patients suffering from diabetes
mellitus type 2 has been alive since the original publication by
Haffner et al. in which the authors suggested that asymptomatic
diabetic patients have the same cardiovascular risk of patients from
the general population with prior myocardial infarction [1]. The
ATP-III embraced this notion and classiﬁed all diabetic patients at
the highest risk independent of all other markers of peril [2]. But, is
it really true that all diabetic patients were created equal? Or is it
appropriate to also risk stratify these patients according to a series
of discriminating criteria? The article by Yeboah et al. [3] in a
previous issue of the journal suggests that the latter may be a more
desirable approach than one based on the simple assumption that
risk is equal for all patients affected by a certain disease. Indeed, we
have seen prior publications in which 15e25% of diabetic patients
harbored no subclinical atherosclerosis, as assessed by coronary
artery calcium (CAC) screening, and these patients suffered an
event rate as low as patients without diabetes [4e7]. On the other
hand, presence of coronary calcium and its progression are har-
bingers of a poor prognosis in diabetes mellitus [5]. However, is theDOI of original article: http://dx.doi.org/10.1016/j.atherosclerosis.2014.07.035.
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patients to achieve better risk stratiﬁcation? The notion that risk
can be differentiated among diabetic patients is examined in the
paper published by Yeboah et al. in this issue of Atherosclerosis [3].
The investigators of two international cohort studies (Multi Ethnic
Study of Atherosclerosis eMESA- and Heinz Nixdorf Recall e HNR-
study) utilized traditional risk factors as well as C-reactive protein
(CRP), CAC score, carotid intima media thickness (cIMT), and ankle
brachial index (ABI) to devise a new risk model to estimate risk of
incident cardiovascular events in asymptomatic diabetic patients.
Of the 1343 patients included in the analyses, 85 (6.3%) suffered an
event during a follow-up period of 8.5 years. This is already an
indirect proof of the fact that not all diabetic patients are at high-
risk according to ATP-III (i.e. >20% at 10 years) since the estimated
event rate was merely 7.5% at 10 years [3]. Of note, the new ACC/
AHA guidelines on the assessment of cardiovascular risk suggest a
risk of 7.5% at 10 years as a cutoff to differentiate low vs high-risk
[8]. In the article by Yeboah et al. [3] CAC was the best predictor of
events among the non-traditional risk markers taken singly. The
investigators then proceeded to select the variables in their com-
bined cohorts that best predicted a hard outcome to develop a new
model. Once they identiﬁed the following variables: age, sex, sys-
tolic blood pressure, duration of diabetes and log CAC score they
compared their new model to the two most frequently used risk
prediction models for diabetes mellitus, the UKPDS and the Fra-
mingham Risk Score. They determined that the new model had
incremental predictive value over the previous ones (area under
the curve ~0.76 for the new model compared to ~0.69 for the older
models). Additionally, the new model demonstrated superior
reclassiﬁcation of risk compared to the older models, allowing
approximately 20% of the patients to be reclassiﬁed to a higher or
lower risk category. The same proportion of ~20% was reclassiﬁed if
the MESA-HNR score was compared to the score introduced by the
very recent ACC/AHA recommendations [8]. When compared to the
ATP-III assumption that all diabetic patients are at high-risk the
MESA-HNR score allowed reclassiﬁcation of 74% of the patients.
Pending the necessary external validation of the MESA-HNR score,
the natural conclusion seems to be that the newmethod is superior
and should be implemented above and beyond all others.
Furthermore, the performance of any of the older models improved
once CAC was inserted in the model and the new MESA-HNRr the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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variables improved the ability of CAC to predict events only
marginally (AUC for model with CAC alone vs CAC and other vari-
ables: 0.74 vs 0.76). This suggests that CAC assessment alone may
help reﬁne risk prediction to the same extent as the more complex
model presented by the authors. Hence, CAC imaging may be all we
need to better capture the heterogeneity of and discriminate risk
among diabetic patients. But is it really that easy? The sad reality is
that while the ATP-III [2] would have misclassiﬁed over 90% of
MESA-HRN cohort low-risk diabetic patients as high-risk, it would
not havemissed any of the high-risk patients. The MESA-HNR score
on the contrary ranked as low to intermediate risk 77% of the pa-
tients who eventually suffered an event [3]. We are faced again
with the same quandary: should we choose a model with high
sensitivity and low speciﬁcity (ATP-III recommendations), or one
with low sensitivity and high speciﬁcity (MESA-HNR score)? What
is preferable when screening for a diseasewith highmorbidity such
as diabetes mellitus? The authors conclude that in the current
environment of cost containment and concern with radiation
exposure an all-inclusive approach that recommends treating all
diabetic patients with statins is preferable. But should we treat all
diabetic patients with aspirin, statins, ACE-inhibitors, drugs for
aggressive glycemic control and diet when the majority of them
may not need them or may not need them for a long time? Are we
to be concerned about the cost of CT imaging and risk of radiation
exposure and not or more than the cost of treatments and their side
effects and the potential risk of unnecessary therapies? “Primum
non nocere” (ﬁrst do no harm) is the principle we swore to observe
in our profession but the impression of the writers is that often we
interpret this notion wrongly: we feel we would hurt our patients
by not intervening on a possible risk rather than choosing wisely
the individual who needs it most. The “hope” for the potential
beneﬁt of our intervention should not induce us to underestimate
the risk associated with it. Though data in diabetic patients are
scanty, aspirin for primary prevention is associated with an abso-
lute 0.1% risk reduction of cardiovascular events at the cost of 2
cases per 1000 patient-year of major bleeding [9]. Statins may have
a more favorable risk-to-beneﬁt proﬁle since their use is associated
with a 1e2% absolute risk reduction of cardiovascular events and an
incidence of 3.4 cases per 100,000 patient-years of rhabdomyolysis
[9]. But is it clear what statins cause as side effect in diabetic pa-
tients? Finally, recent data prompted the European Medicines
Agency (EMA) to endorse restrictions on the concomitant use of
drugs that act on the renineangiotensinealdosterone system due
to the risk of hyperkalemia, and declining renal function (http://
www.ema.europa.eu/docs/en_GB/document_library/Press_
release/2014/05/WC500167421.pdf).
The authors of this editorial are convinced that the presence of
subclinical atherosclerosis could be a useful marker to identify
patients at greater risk and in greater need of intervention “now”.
However a few aspects need to be elucidated before recom-
mending subclinical atherosclerosis screening. What is thepreferable tool for subclinical atherosclerosis assessment? Should
it be a tool that assesses functional or morphologic damage of the
arterial tree [10]? In light of the multiple factors that may cause
an instantaneous perturbation of the arterial function, it is likely
that a morphological assessment such as CAC measurement may
provide a more accurate assessment of the cumulative risk
exposure for the single individual. This might explain why dura-
tion of diabetes mellitus (although self reported) but not Ankle
Brachial Index (ABI) was identiﬁed as a meaningful variable for
the MESA-HNR model. What is the best recording site for sub-
clinical atherosclerosis evaluation? How long is the warranty
period of a negative result such as “zero” CAC score? Is this
approach safe and cost-effective? While fueling the debate on
how to stratify risk in diabetic patients, Yeboah and coworkers
shed some light on the potential utility of subclinical disease
screening for personalized medicine. However, further conﬁr-
mation is needed before this approach is embraced in daily
practice. Until future data become available, we ought to face the
“Innocent Prisoner's dilemma”: free with suspicion of guilt, or
jailed while innocent? Is it better to expose our patients to un-
necessary cardiovascular risk (by not treating) or to an unnec-
essary risk associated with interventions (treat them all)?References
[1] Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease
in subjects with type 2 diabetes and in nondiabetic subjects with and without
prior myocardial infarction. N. Engl. J. Med. 1998;339:229e34.
[2] Third report of the National Cholesterol Education Program (NCEP) expert
panel on detection, evaluation, and treatment of high blood cholesterol in
adults (Adult Treatment Panel III) ﬁnal report. Circulation 2002;106:
3143e421.
[3] Yeboah J, Erbel R, Delaney JC, et al. Development of a new diabetes risk pre-
diction tool for incident coronary heart disease events: the multi-ethnic study
of atherosclerosis and the Heinz Nixdorf recall study. Atherosclerosis
2014;236:411e7.
[4] Raggi P, Shaw LJ, Berman DS, et al. Prognostic value of coronary artery calcium
screening in subjects with and without diabetes. J. Am. Coll. Cardiol. 2004;43:
1663e9.
[5] Raggi P, Cooil B, Ratti C, et al. Progression of coronary artery calcium and
occurrence of myocardial infarction in patients with and without diabetes
mellitus. Hypertension 2005;46:238e43.
[6] Anand DV, Lim E, Hopkins D, et al. Risk stratiﬁcation in uncomplicated type 2
diabetes: prospective evaluation of the combined use of coronary artery cal-
cium imaging and selective myocardial perfusion scintigraphy. Eur. Heart J.
2006;27:713e21.
[7] Galassi A, Spiegel DM, Bellasi A, et al. Accelerated vascular calciﬁcation and
relative hypoparathyroidism in incident haemodialysis diabetic patients
receiving calcium binders. Nephrol. Dial. Transplant. 2006;21:3215e22.
[8] Goff Jr DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the
assessment of cardiovascular risk: a report of the American College of Car-
diology/American Heart Association Task Force on Practice Guidelines. Cir-
culation 2014;129:S49e73.
[9] Dietrich E, Davis K. A statin a day to keep the doctor away? Comparing aspirin
and statins for primary prevention of cardiovascular disease. Ann. Pharmac-
other. 2014;48:1238e41.
[10] Bellasi A, Raggi P. Vascular calciﬁcation in chronic kidney disease: usefulness
of a marker of vascular damage. J. Nephrol. 2011;24(Suppl. 18):S11e5.
